Seer

San Francisco, United States Founded: 2017 • Age: 9 yrs
Proteomics platform developed for early cancer and neurological disease detection.

About Seer

Seer is a company based in San Francisco (United States) founded in 2017. It operates as a Product-as-a-Service, and HealthTech. Seer has raised $127.5 million across 7 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 134 employees as of December 31, 2024. Seer offers products and services including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center. Seer operates in a competitive market with competitors including Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector, among others.

  • Headquarter San Francisco, United States
  • Employees 134 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Seer, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $13.95 M
    -8.13
    as on Dec 31, 2024
  • Net Profit
    $-86.6 M
    -0.37
    as on Dec 31, 2024
  • EBITDA
    $-94.15 M
    5.25
    as on Dec 31, 2024
  • Total Equity Funding
    $127.5 M (USD)

    in 7 rounds

  • Latest Funding Round
    $55 M (USD), Series D

    Jul 22, 2020

  • Investors
  • Employee Count
    134

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Seer

Seer is a publicly listed company on the NASDAQ with ticker symbol SEER in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: SEER . Sector: Health technology · USA

Products & Services of Seer

Seer offers a comprehensive portfolio of products and services, including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Deep, rapid, unbiased proteomics analysis at scale provided.

Proteomics data is analyzed quickly and easily here.

White-glove service programs for proteomics are offered now.

People of Seer
Headcount 50-200
Employee Profiles 54
Board Members and Advisors 15
Employee Profiles
People
Daniel Kim
Field Service Engineer II
People
Kevin Quach
System Test Engineer
People
Josh Silva
Head Of Sales Operations
People
Tianyu Wang
Senior Research Associate

Unlock access to complete

Board Members and Advisors
people
Josh Coon
Advisor
people
Chris Mason
Advisor
people
Robert Langer
Co-Chairman, Scientific Advisory Board
people
Terry McGuire
Independent Director

Unlock access to complete

Funding Insights of Seer

Seer has successfully raised a total of $127.5M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $55 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series D — $55.0M
  • First Round

    (01 Jan 2017)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2020 Amount Series D - Seer Valuation Fidelity Investments , aMoon
Dec, 2019 Amount Series D - Seer Valuation aMoon
Sep, 2019 Amount Grant - Seer Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Seer

Seer has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life sciences focused VC firm funding companies in the US and Europe
Founded Year Domain Location
Long-term private equity investments in transformational opportunities are pursued.
Founded Year Domain Location
Venture capital investments in healthcare are focused on by aMoon.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Seer

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Seer

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Seer Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Seer

Seer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Solutions for biomarker discovery and diagnostic testing are provided.
domain founded_year HQ Location
Cloud-based protein-modeling software is developed for drug discovery.
domain founded_year HQ Location
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Seer

When was Seer founded?

Seer was founded in 2017.

Where is Seer located?

Seer is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Is Seer a funded company?

Seer is a funded company, having raised a total of $127.5M across 7 funding rounds to date. The company's 1st funding round was a Grant of $2.04M, raised on Jan 01, 2017.

How many employees does Seer have?

As of Dec 31, 2024, the latest employee count at Seer is 134.

What is the annual revenue of Seer?

Annual revenue of Seer is $13.95M as on Dec 31, 2024.

What does Seer do?

Seer, Inc. is dedicated to pioneering innovative technologies for proteomics research. The company is engaged in developing tools like the Proteograph Product Suite to enable deep, rapid, and unbiased proteomics at scale. Solutions such as the Proteograph Analysis Suite are provided for efficient data analysis. Operating in the healthcare and biotechnology sectors, Seer aims to eliminate barriers in proteomics, empowering the scientific community to achieve exceptional outcomes. Their technology is utilized by top researchers and featured in numerous scientific publications. The mission is centered on decoding the proteome to improve human health globally.

Who are the top competitors of Seer?

Seer's top competitors include Alector, Maze Therapeutics and Metabolon.

What products or services does Seer offer?

Seer offers Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center.

Is Seer publicly traded?

Yes, Seer is publicly traded on NASDAQ under the ticker symbol SEER.

Who are Seer's investors?

Seer has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Aju IB Investment, and HBM Healthcare Investments.

What is Seer's ticker symbol?

The ticker symbol of Seer is SEER on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available